Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine in Hospitalized Adult Subjects Infected With Human Metapneumovirus
NCT03502694Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of lumicitabine in human metapneumovirus infection (HMPV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Area Under the Concentration-Time Curve (AUC) of Human Metapneumovirus (hMPV) Viral Load. Planned start Nov 2018; status: withdrawn.
02
Drugs
lumicitabine
03
Conditions
human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT03502694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502694.